KEY MEMBERS
NeoImmuneTech, Inc. (NIT) is led by seasoned executives relentlessly pursuing the development of novel drug in immuno-oncology.
Luke Oh Ph.D. - President and Chief Executive Officer
Dr. Luke Oh has a Ph.D. in Neuroimmunology from the McGill University(Montreal, Canada), and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Also Dr. Oh is an expert in regulatory experience at the U.S. FDA. He has over 20 years of experience, including experience overseeing clinical operations as Samsung Bioepis.
Dr. Luke Oh has a Ph.D. in Neuroimmunology from the McGill University(Montreal, Canada), and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Also Dr. Oh is an expert in regulatory experience at the U.S. FDA. He has over 20 years of experience, including experience overseeing clinical operations as Samsung Bioepis.
KEY MEMBERS
Clinical Division
Byung Ha Lee
Ph.D.
Chief Scientific Officer
/ Head of Clinical Division
Hye Jeong
M.D.
Medical Director of Drug
Safety and Pharmacovigilance
Sara Ferrando Martinez
Ph.D.
Head of Clinical Sciences
Advisor
Jiyoung Joo
Advisor
Quality Assurance Division
Hee Yong Jeong
Director
of CMC QA
Richard Sloma
Senior Director of
Clinical QA
CMC Division
Eun Jeong Bae
Head of CMC Division
Regulatory Affairs Division
Alicia Staz
RA Director
Research Institute
Donghoon Choi
Ph.D.
Chief Technology Officer
/ Head of Research Institute
Business Development
Daniel Rho
Director of Business
Development
Global Strategy Department
Hyun Jee Kim
Head of Global
Strategy Department
Finance Division
Tae Woo Kim
CPA
Chief Financial Officer
/ Head of Finance Division
Management Division
Gene Namgoong
Chief Operating Officer
/ Head of Management Division
Dana Wyche
IT Director
Soon Phil Lee
Head of Management Department (KR)